Autolus Therapeutics (NASDAQ: AUTL) reported Q4 EPS of ($0.34), $0.09 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $24.29 million versus the consensus estimate of $24.89 million.

For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.